PD1 Non-Small Cell Lung Cancer Treatment Market

PD1 non-small cell lung cancer treatment sales will grow through 2036, led by pembrolizumab at 62.0% of the drug type segment in 2026. The market was valued at USD 31.74 billion in 2025 and is expected to be worth USD 81.90 billion by 2036, creating an incremental opportunity of USD 47.30 billion.